PubMed Health⌕ Search

Biomedical subjects

Jennifer Adelson Mitty

Publications and source records attributed to Jennifer Adelson Mitty.

4 recordsLinked to original sources
PubMed2006

Once-daily therapies for the treatment of HIV infection.

For patients initiating antiretroviral therapy, there are several well-tolerated once-daily regimens from which to choose. Once-daily antiretroviral therapy may be ideal for patient adherence and convenience. However, results of a few recent clinical trials exploring new once-daily regimens have shown that one cannot assume that any three-drug combination will be successful. Once-daily therapy options for treatment-experienced patients are more limited but may be successful depending on prior antiretroviral treatment exposure and resistance mutations. Current approaches to once-daily therapy include simplifying successful regimens and investigating novel antiretroviral agents with long half-lives.

Anti-HIV Agents↗
PubMed2003

Directly observed therapy (DOT) for individuals with HIV: successes and challenges.

Many HIV-infected individuals have not reaped the benefits of combination antiretroviral therapy due to inability either to adhere to medications or to access care. It is now recognized that innovative approaches are needed to increase access and adherence to highly active antiretroviral therapy (HAART), especially among these hard-to-reach populations. Due to the success of directly observed therapy (DOT) for the treatment of Mycobacterium tuberculosis (TB), our group and others have questioned whether DOT can be adapted to deliver HAART to hard-to-reach communities. In this review, we discuss the results of pilot programs that have utilized DOT in multiple different settings and use case studies to explore the diverse issues that can arise when implementing these programs. As we continue to gain more experience with observed therapy, we will be able to better identify the key components for a successful intervention.

Adult↗
PubMed2002

Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress.

The principle of directly observed therapy (DOT) has its roots in the treatment of tuberculosis (TB), for which DOT programs have improved cure rates in hard-to-reach populations. Human immunodeficiency virus (HIV) and TB affect similar populations, and there are concerns about both regarding the development of drug resistance associated with poor adherence to therapy. Accordingly, DOT may benefit certain HIV-infected people who have difficulty adhering to highly active antiretroviral therapy. However, important differences exist in the treatment of these diseases that raise questions about how DOT can be adapted to HIV therapy. DOT for management of HIV infection has been effective among prisoners and in pilot programs in Haiti, Rhode Island, and Florida. Although DOT can successfully treat HIV infection in marginalized populations in the short term, a multitude of questions remain. This review provides an account of the preliminary development of DOT programs for the treatment of HIV-infected individuals.

Antiretroviral Therapy, Highly Active↗